Grail reports first data from CCGA study

Grail Inc. (Menlo Park, Calif.) reported initial data from a lung cancer substudy of its observational Circulating Cell-Free Genome Atlas (CCGA) study, which aims to create a detailed atlas of cancer genetics. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

Grail used three prototype sequencing assays to detect plasma cell-free DNA (cfDNA) mutations and other genomic changes from blood samples of 749 control subjects without cancer and 878 patients with newly diagnosed untreated cancer. The assays, which could be used in the development of an early cancer detection test, include targeted sequencing, whole-genome sequencing (WGS) and whole-genome bisulfite sequencing (WGBS)...